(Q40024329)

16 September 2017

title

Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes (English)

1 reference

16 September 2017

1 reference

1 reference

Newcastle disease virus

object named as

Newcastle disease virus

1 reference

F Pühler

1

1 reference

16 September 2017

J Willuda

2

1 reference

16 September 2017

J Puhlmann

3

1 reference

16 September 2017

D Mumberg

4

1 reference

16 September 2017

A Römer-Oberdörfer

5

1 reference

16 September 2017

R Beier

6

1 reference

16 September 2017

publication date

17 January 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

15

1 reference

16 September 2017

issue

5

1 reference

16 September 2017

page(s)

371-383

1 reference

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Viruses in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Newcastle disease virus (NDV): brief history of its oncolytic strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Newcastle disease virus selectively kills human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Generation of recombinant lentogenic Newcastle disease virus from cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Recombinant Newcastle disease virus as a vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

ED-B fibronectin as a target for antibody-based cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Genome replication of Newcastle disease virus: involvement of the rule-of-six

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

The preferential cytotoxicity of reovirus for certain transformed cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Replication-selective oncolytic viruses in the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Transport of molecules across tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Intrabodies as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

Tumor immunity after viral oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

inferred from DOI database lookup

7 January 2021

based on heuristic

Infectious rabies viruses from cloned cDNA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

inferred from DOI database lookup

7 January 2021

based on heuristic

Delivery of molecular and cellular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303095

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3303095

1 reference

Dimensions Publication ID

16 September 2017

1019860817

0 references

1 reference